Andere Sprachen Genmab A/S BOERSE MUENCHEN

Aktien

565131

DK0010272202

GE9

Realtime BOERSE MUENCHEN Andere Börsenplätze 14:32:44 01.07.2024			% 5 Tage	% 1. Jan.
231,1 ^EUR	-1,32 %		-3,94 %	-18,82 %

28.06.	Lymphom-Therapie von Genmab und AbbVie in der EU zur Zulassung empfohlen	MT
28.06.	AbbVie, Genmab erhalten positives europäisches Gutachten zur Marktzulassung für mögliche Lymphom-Behandlung	MT

Andere Sprachen

Erhalten Sie Zugang zu allen Nachrichten über alle Unternehmen: Verpassen Sie keine profitable Anlagechance mehr!

100% kostenlose Registrierung

Genmab A/S - Completion of Share Buy-back Program	28.06.
Would you like some more inflation?	28.06.
Genmab, AbbVie's Lymphoma Therapy Recommended for Approval in EU	28.06.
AbbVie, Genmab Receive Positive European Opinion on Marketing Authorization for Possible Lymphoma Treatment	28.06.
En Direct des Marchés : Renault, L'Oréal, Schneider Electric, Atos, Nokia, Meta Platforms...	28.06.
Vous reprendrez bien un peu d'inflation ?	28.06.
Epcoritamab (TEPKINLY®) Receives Positive CHMP Opinion for the Treatment of Adults with Relapsed/ Refractory Follicular Lymphoma	28.06.
Epcoritamab (TEPKINLY®) Receives Positive CHMP Opinion for the Treatment of Adults with Relapsed/ Refractory Follicular Lymphoma	28.06.
AbbVie Receives Positive CHMP Opinion for Epcoritamab for the Treatment of Adults with Relapsed/Refractory Follicular Lymphoma	28.06.
Bolsa de Madrid: ¿Le apetece un poco más de inflación?	28.06.
Genmab Closes DKK3.5 Billion Share Buyback Early	28.06.
Completion of Share Buy-back Program	27.06.
Genmab A/S - EPKINLY Approved by U.S. FDA for Patients with Relapsed or Refractory Follicular Lymphoma	27.06.
AbbVie - U.S. Food and Drug Administration Grants Second Approval for EPKINLY to Treat Patients with Relapsed or Refractory Follicular Lymphoma	27.06.
Genmab Gets FDA Approval for Follicular Lymphoma Treatment	27.06.
Genmab Wins US Approval for Follicular Lymphoma Treatment	27.06.
EPKINLY® (epcoritamab-bysp) Approved by U.S. FDA for Patients with Relapsed or Refractory (R/R) Follicular Lymphoma (FL)	27.06.
EPKINLY® (epcoritamab-bysp) Approved by U.S. FDA for Patients with Relapsed or Refractory (R/R) Follicular Lymphoma (FL)	27.06.
Genmab A/S Announces That the U.S. Food and Drug Administration Approved Epkinly® (Epcoritamab-Bysp) for the Treatment of Adults with Relapsed or Refractory Follicular Lymphoma After Two or More Lines of Systemic EPKINLY	27.06.
U.S. Food and Drug Administration Grants Second Approval for AbbVie's EPKINLY (epcoritamab-bysp) to Treat Patients with Relapsed or Refractory Follicular Lymphoma	27.06.

Keine Ergebnisse zu dieser Suche

Alle Nachrichten Analystenempfehlungen Wichtige Fakten Insiders Transkripte Pressemitteilungen Offizielle Publikationen Andere Sprachen Trading-Ideen MarketScreener Artikel MarketScreener Analysen

Filter

Schlagzeilen

GENMAB : Guter Start ins Jahr 2024; Prognose unverändert

Am 03. Mai 2024 um 19:08 Uhr

Genmab A/S: Die andere dänische Erfolgsgeschichte im Gesundheitsbereich

Am 15. Juni 2023 um 09:28 Uhr